Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. - Wikidata - awgldk - TriplyDB

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

http://www.wikidata.org/entity/Q48370561

about

Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Biomarkers of therapeutic response in multiple sclerosis: current status Antidrug Antibodies: B Cell Immunity Against Therapy Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab Drug therapy for multiple sclerosis.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.Protein-based matrix interferences in ligand-binding assays.Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine.The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.Body fluid biomarkers for multiple sclerosis--the long road to clinical application.Disease activity return after natalizumab cessation in multiple sclerosis.The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine.Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Natalizumab treatment of multiple sclerosis: new insights.Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor.Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.Soluble interleukin 23 receptor gene therapy with adeno-associated vectors for the treatment of multiple sclerosis.The case for measuring anti-drug antibodies in people with multiple sclerosis.Prediction of natalizumab anti-drug antibodies persistency.Disease activity following pregnancy-related discontinuation of natalizumab in MS.Smokers run increased risk of developing anti-natalizumab antibodies.The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab.Identification of Peptide Mimotope Ligands for Natalizumab

P2860

Q26747193-17215DB2-073B-47EB-8685-779D5882D3B2 Q26798434-E5D913CB-1E03-47A8-8AA6-7BD949BABA45 Q27012726-FBD0DD63-F9E5-4CBE-A7D0-0AF6E783F338 Q28082303-8774CDF3-AD58-4D73-9B19-948E169CCACB Q30659100-B41B1C6E-67BB-40E6-9123-6C3D9C7A621E Q33755345-FDEF094D-51F8-476D-80F0-5B46A2A3CB10 Q33895664-B24C461C-E156-49A8-ADDE-5BA5907323F4 Q33990246-6C64E9CB-8169-4268-8C07-87FC10A9F99C Q34468304-F96B8B05-DAAF-4EA7-8EA1-18E6E4A74BDB Q36214720-C04279E0-E4AF-4F77-ADA0-169DC2A4C927 Q36669122-06CC88D2-1062-4767-8032-94F2A5FDD5E1 Q37045253-8D8B6305-C8F7-40C0-871A-222CA772D92D Q37690014-E23E6A93-D9AA-4878-94B4-BCB23D92ABA3 Q37696989-1FB1741D-DFB5-4DE6-9B2A-89D549E5F493 Q38211931-D718D53C-07F6-42ED-AE72-9F8189B86599 Q38218692-F1DE0664-59C4-471B-A832-CA39CE42EE2D Q38222900-95E1F9B1-C935-48AC-8B83-AFC5E97F519D Q38364547-DC5C743F-7FEE-4141-A62D-012F275D5166 Q38590773-2A400041-3B12-45B9-B324-3A0F4AB7CE81 Q38779091-9F5E4C08-D55C-47A1-917A-086E2E8C335F Q38796218-0CAD8DF5-7BDB-49DC-8BEB-07CF4B4581D1 Q38802998-2DCA6E55-A813-467A-AFBB-7268D35E322A Q38842554-19312D11-E765-4F3C-9F15-CAE35C20FC70 Q38960854-91F2F9F5-02A6-43E7-8148-256F14CA045D Q38984981-1E7B7E61-6DE1-4850-AF40-733345E0B74F Q39021942-DF1CC261-62DA-42A3-93D8-22AA56AF6F85 Q39048568-0736C1B3-2039-4E95-82B6-C68B4FFC6338 Q40077487-AFCE0560-D12D-408C-BEE7-54CCB6B11D83 Q40167890-95BF8216-7529-4592-B798-371B54D498B5 Q41198127-33086F1F-604D-45B3-ACBD-DCAC9B57F792 Q42266048-79C9F534-ABDD-47E1-AC7B-EE859A3016C3 Q42373188-EEB35E27-CFB6-422B-9905-E169FFEECD81 Q45840225-A56A7B56-3488-4B61-8299-BDA273D54770 Q48077993-B542334E-495D-44FD-861D-858C837C4E62 Q48237799-A70A9734-372C-43EF-ABA9-FEB6F0991313 Q49590553-AFD8FDE5-CC55-44CA-ADD6-813DD47C8C2B Q50800499-E14F473A-153E-457E-AD52-586560C9A0A1 Q50998405-950FD3B3-0A8B-44FE-B180-4AC61DB5E40A Q55342245-70B553B5-D9EE-41DE-BA38-7B2F9788EE0E Q56876832-5483A517-8FC1-45A5-8033-86B9B0C85974

P2860

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

http://www.wikidata.org/entity/Q48370561

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Clinical relevance of serum na ...... ibodies in multiple sclerosis.

@en

Clinical relevance of serum na ...... ibodies in multiple sclerosis.

@nl

type

label

Clinical relevance of serum na ...... ibodies in multiple sclerosis.

@en

Clinical relevance of serum na ...... ibodies in multiple sclerosis.

@nl

prefLabel

Clinical relevance of serum na ...... ibodies in multiple sclerosis.

@en

Clinical relevance of serum na ...... ibodies in multiple sclerosis.

@nl

P1433

Q48370561-515A76B4-F1E1-40F5-964F-368524AA4C9A

P1476

Q48370561-7278C06F-5E55-43D7-9190-AE2A2966919C

P2093

Q48370561-064C240C-4915-4670-A396-EF090976647A

Q48370561-1E915C2E-C566-4D5E-8065-95216777CD3B

Q48370561-52472564-8782-40ED-9117-5B59840AA028

Q48370561-6CF2A9D1-0897-497B-8B99-BE8B689573C2

Q48370561-B0B0DB40-D9E0-48CB-82DA-55AB8BA8EE28

Q48370561-B76FB012-13CB-4A97-B989-3C50F6CE1A5D

Q48370561-C0665D3C-33A6-4FCB-A3B1-16B785D860B4

Q48370561-CADEC43F-F7C6-40BF-8DCC-F028DD46619E

Q48370561-E163A15E-F166-46F0-8DAE-3F51FCC05705

P2860

Q48370561-0D86E1D2-3A3A-4920-9329-E8B0CF6EDE35

Q48370561-16B9768B-B741-4DE7-AB5D-862AD2C6FF76

Q48370561-321D6013-F099-4169-A3F7-467E8C35A7B0

Q48370561-3B6D6A96-E079-478C-8C33-A5F511F4A0E9

Q48370561-4BB5A475-8464-4EB4-9BFE-B79AD083B03C

Q48370561-6A406F1C-D89F-42D2-9C99-1AE9D4D98F0E

Q48370561-8102BDC4-BBD0-4E49-87C0-65150B345957

Q48370561-81182993-F254-40EF-85A5-6EE7098CAE7D

Q48370561-85AA98C7-28B8-4D61-BBF2-701C69FC1290

Q48370561-8E46E266-5BCB-4BF7-AC32-439FE00C89F0

P304

Q48370561-6B95B108-5AF8-4508-B773-2CA933C8AD23

P31

Q48370561-857B34F9-3548-48A9-B937-7A894DBB59DF

P356

Q48370561-A5B7FA64-FED0-400F-AD49-AD472F7BC046

P433

Q48370561-1DBC808F-CD2A-4D7E-8EAA-04CB4724C33C

P478

Q48370561-B12EC282-E480-41F4-A8BB-C930C141AC26

P50

Q48370561-C9085701-AF81-4190-8278-497B07C1A026

P577

Q48370561-BC4A249D-C926-43DF-8406-106D21C623F0

P698

Q48370561-B9785B0A-99A1-4B0E-8DB5-810E13CE7DEF

P921

Q48370561-0DF1A284-32AC-46C3-A350-FF55B3B18C22

Q48370561-CA15072F-C283-4C39-8519-75CBC45F6D61

P356

1352458512460604

P1433

Multiple Sclerosis Journal

P1476

Clinical relevance of serum na ...... ibodies in multiple sclerosis.

@en

P2093

Alexandra Seewann

http://www.w3.org/2001/XMLSchema#string

Anke Vennegoor

http://www.w3.org/2001/XMLSchema#string

Bernard Mj Uitdehaag

http://www.w3.org/2001/XMLSchema#string

Chris H Polman

http://www.w3.org/2001/XMLSchema#string

Eva Mm Strijbis

http://www.w3.org/2001/XMLSchema#string

Gertjan Wolbink

http://www.w3.org/2001/XMLSchema#string

Joep Killestein

http://www.w3.org/2001/XMLSchema#string

Lisanne J Balk

http://www.w3.org/2001/XMLSchema#string

Theo Rispens

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases.

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

P304

593-600

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1352458512460604

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Frederik Barkhof

P577

2012-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22992450

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis